FibroGen (FGEN) Set to Announce Earnings on Monday

FibroGen (NASDAQ:FGEN) is scheduled to be releasing its earnings data after the market closes on Monday, May 6th. Analysts expect FibroGen to post earnings of ($0.31) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The business had revenue of $27.14 million during the quarter, compared to analysts’ expectations of $40.00 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Trading Up 0.9 %

FibroGen stock opened at $1.14 on Friday. The company has a market capitalization of $113.40 million, a PE ratio of -0.39 and a beta of 0.88. FibroGen has a 12 month low of $0.33 and a 12 month high of $19.47. The stock has a 50-day moving average price of $1.73 and a two-hundred day moving average price of $1.23.

Insider Transactions at FibroGen

In related news, CEO Thane Wettig acquired 50,000 shares of the stock in a transaction dated Thursday, March 7th. The stock was bought at an average cost of $1.91 per share, for a total transaction of $95,500.00. Following the completion of the transaction, the chief executive officer now directly owns 470,178 shares of the company’s stock, valued at $898,039.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.39% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a research report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. According to data from MarketBeat.com, FibroGen currently has an average rating of “Hold” and an average target price of $17.00.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.